A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 191 participants.
Also called NCT06616974
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 191 participants
- Sponsor
- Tectonic Therapeutic
- Registry
-
NCT06616974
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Armenia, Australia, Austria, Belgium, Bulgaria, Georgia, Germany, Latvia, Moldova, New Zealand, Poland, Portugal, Romania, Serbia, Spain, Ukraine
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06616974. Randomized; double masking; primary purpose treatment. Start 2024-09-04 (actual); primary completion 2026-11-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
- Condition
- Pulmonary Hypertension
- Intervention (Drug)
- TX000045- Dose A
- Intervention (Drug)
- TX000045- Dose B
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tectonic Therapeutic
Record details
- Record id
cardio:ct-nct06616974- Content hash
4d4951a251c8ff5bbf0e980be9b00c4d7d42676d9087f73fbc11ffaec70c17e3